|
Malcolm E. Kenney
Ph.D.
BRTT Co-Investigator
|
|
A major part of Dr. Kenney’s research deals with studies giving basic information necessary for the application of phthalocyanines in microelectronic gas sensing, optical data storage, nonlinear optical devices, and in recent years especially in photobleaching and photodynamic and photothermal therapies (PDT and PTT). Another part of his research deals with nanosheet and nanotube organosilicon polymers. In collaboration with Dr. Oleinick and others at Case, he discovered the phthalocyanine PDT drug Pc 4. He has since provided much chemical information about the drug. He has assisted clinicians in the
Ireland
Cancer
Center
in developing an ongoing Phase I trial of Pc 4 for dermal malignancies in which it is administered intravenously, and in opening a new trial in which topical application is being used. A license for the use of Pc 4 for red blood cell sterilization was granted to the
new York
Blood
Center
and its spin-off Vitex by Case and UHC. Commercial development of Pc 4 for cancer and other indications is being launched. Dr. Kenney is collaborating with Drs. Oleinick and Burda to design improved fluorescent nanoparticle probes that can target specific sites in or on tumor cells and signal events in their vicinity. In collaboration with scientists at Procter and Gamble in
Cincinnati
, Dr. Kenney has participated in the development of a phthalocyanine photobleach for use in ordinary household detergents (such as Tide) in sunny geographies of the world where line drying of clothes is used. This photobleach gives excellent test results in the hands of consumers. The photobleach technology package has been donated to Case by Procter and Gamble, and Case is actively negotiating rights for its use with a major detergent intermediates producer. US and foreign patents have been issued for various aspects of these various efforts.
